An analysis of cancer death records across the country, by researchers at the University of Washington, has identified clusters of counties that had a particularly high rate of mortality depending on the cancer type.
An analysis of cancer death records across the country, by researchers at the University of Washington, has identified clusters of counties that had a particularly high rate of mortality depending on the cancer type.
One of the leading causes of death in the United States, cancer also places a significant economic burden on the country. An annual report by the CDC, the National Cancer Institute, and the American Cancer Society in early 2016 showed that cancer-related deaths have been on the decline. One can attribute the decline to a combination of factors:
The current report in JAMA was based on the hypothesis that information derived at the county-level can help researchers gain more insight on the impact of public health programs, which are designed and implemented locally. The authors write that such data can help clinicians understand the needs of their local community and also help identify cancer hotspots, which can lead to the primary cause of spikes in incidence or death.
The study included death records from the National Center for Health Statistics (NCHS) and population counts from the Census Bureau, the NCHS, and the Human Mortality Database from 1980 to 2014 were used. The study focused on 29 cancers—including stomach, colon, liver, lung, melanoma, brain, kidney, Hodgkin and non-Hodgkin lymphoma, and multiple myeloma—to estimate county-level mortality rates. The primary outcomes were age-adjusted county, year, sex, and cancer type.
The following table shows the recorded death rates across the country during the period between 1980 and 2014, based on cancer type:
Cancer Type
Death Rate
Tracheal, bronchus, and lung
5,656,423
Colon and rectum
2,484,476
Breast
1,573,593
Pancreatic cancer
1,157,878
Uterine cancer
209,314
Kidney cancer
421,628
Liver cancer
487,518
Testicular cancer
13,927
Non-Hodgkin lymphoma
829,396
Overall, a 20.1% decrease in the cancer death rate was observed for the study period. However, the authors noted that the death rate varied substantially across counties. In 1980, mortality ranged from 130.6 per 100,000 in Summit County, Colorado, to 386.9 in North Slope Borough, Alaska. In 2014, the numbers ranged from 70.7 per 100,000 for Summit County, Colorado, to 503.1 per 100,000 for Union County, Florida.
Further, the authors observed a cancer type—dependent variation in the death rate, with specific clusters of counties having a high mortality rate. Clusters of breast cancer were documented in southern states, along the Mississippi river; incidence of liver cancer was high along the Texas–Mexico border; and kidney cancer rates spiked in several states, including North and South Dakota and counties in West Virginia, Ohio, Indiana, Louisiana, Oklahoma, Texas, Alaska, and Illinois.
The authors emphasize that curating county-level data highlights local patterns that would otherwise be lost in state or national numbers. This data, they write, can inform decisions on preventive efforts, access to care, and appropriate treatment; they can also help identify worsening incidence, inadequate access to quality treatment, or other etiological factors involved.
Reference
Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, et al. Trends and patterns of disparities in cancer mortality among US counties, 1980-2014 [published online January 24, 2017]. JAMA. 2017;317(4):388-406. doi: 10.1001/jama.2016.20324.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
2 Commerce Drive
Cranbury, NJ 08512